Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
March 05, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
January 08, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces CFO Departure
January 03, 2024
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
December 01, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
November 02, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
October 24, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
October 13, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
October 04, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
September 05, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
August 31, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Chief Medical Officer Succession
August 08, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
August 04, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
June 28, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
June 07, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
June 05, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
May 08, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FHTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.